Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Date:8/31/2013

oral anticoagulants (renal impairment, low body weight, or concomitant use of certain p-glycoprotein inhibitors) who received edoxaban 30 mg according to the study protocol. The reduced dose of edoxaban was found to have an efficacy profile consistent with the overall study cohort, with fewer recurrent VTE events in patients receiving 30 mg edoxaban (n=733) compared to warfarin (n=719) (VTE recurrence of 3.0% vs. 4.2%; HR, 0.73; 95% CI, 0.42 to 1.26). Clinically relevant bleeding in patients receiving edoxaban 30 mg was significantly lower compared to warfarin (7.9% vs. 12.8%, respectively) (HR, 0.62; 95% CI, 0.44 to 0.86).1

Among patients with DVT (n=4,921), VTE recurrence was similar in the edoxaban and warfarin groups (3.4% vs. 3.3%, respectively) (HR, 1.02; 95% CI, 0.75 to 1.38), while the incidence of recurrent VTE among patients with PE (n=3,319) was numerically lower for patients treated with once-daily edoxaban compared to warfarin (2.8% vs. 3.9%, respectively) (HR, 0.73; 95% CI, 0.50 to 1.06). Additionally, in a sub-group analysis, patients with severe PE and evidence of right ventricular dysfunction (defined as NT pro-BNP >/= 500 pg/mL, n=938) treated with edoxaban had a 48% lower risk of recurrent symptomatic VTE compared to warfarin (3.3% vs. 6.2%, respectively) (HR, 0.52; 95% CI, 0.28 to 0.98).1

"Hokusai-VTE was designed to include a broad range of VTE patients, including those with severe pulmonary embolism, and we are therefore pleased that the study found that edoxaban administered once-daily is as efficacious as warfarin for the prevention of recurrent symptomatic VTE while significantly reducing the risk of bleeding," said Harry Büller, MD, PhD, Professor of Internal Medicine, Chairman of the Department of Vascular Medicine at the Academic Medical Center in Amsterdam, The Netherlands and Chairman of the Hokusai-VTE steering committee. "A promising finding was the sizeable re
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
2. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
6. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
7. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
10. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
11. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its previously announced registered offering of common shares in ... Pursuant to the Offering, the Company issued 7,286,432 common ... aggregate gross proceeds of approximately $1.45 billion. On March ... and Exchange Commission a final prospectus supplement to its ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... March 27, 2015  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the reporting of data from a ... for Injection with the Delcath Hepatic Delivery System ... at the Society of Surgical Oncology (SSO) Annual ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... Jan. 28, 2011 Drug safety remains front and ... the agency strives to improve the public,s perception of ... improving its reputation among consumers and recognizes that its ... important role in that effort. One issue ...
... Burg Simpson Eldredge Hersh & Jardine, P.C., one of the ... that shareholder, Seth. A. Katz, has been appointed by the ... the Plaintiffs, Steering Committee in the multidistrict litigation against DePuy Orthopaedics, ... Hip System. In August 2010, DePuy Orthopaedics, Inc., ...
Cached Medicine Technology:Navigating the Gray Areas of Post-Marketing Surveillance 2Burg Simpson Leads National Litigation Against DePuy Orthopaedics, Inc. 2
(Date:3/28/2015)... Centurion Service Group will be hosting a live ... at their Las Vegas warehouse, located at 4606 Andrews St. ... consists of equipment from hospitals and surgery centers from around ... , Buyers will find items of all types including ... one-stop-shop,” said Erik Tivin, CEO of Centurion. , Among the ...
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
(Date:3/28/2015)... 28, 2015 Healthpointe’s otolaryngologists, medical practitioners ... throat disorders, are now offering a wide variety ... which is characterized by the presence of phantom sounds ... people, tinnitus is a prevalent symptom that can arise ... is non-fatal, tinnitus can impede a person’s quality of ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
(Date:3/27/2015)... FL (PRWEB) March 27, 2015 Florida Hospital ... Storm as the team’s exclusive health care provider for the ... provider, Florida Hospital provides medical care and an athletic trainer ... Storm will kick off its season against the Cleveland Gladiators ... , “This partnership is extremely important to us as it ...
Breaking Medicine News(10 mins):Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3
... M. Jackson Foundation for the Advancement of Military Medicine, ... the Health Sciences (USU) doctoral students to receive fellowships ... 1988, includes two Henry M. Jackson Fellowships and one ... and travel support. Jeremy Gilbreath, a ...
... A broad panel of leaders representing health care, academic ... in the content and format of U.S. graduate medical ... effectively and efficiently to meet public needs. ... for overhauling the training of newly minted physicians - ...
... of the University of California and a Southern California ... commercialize their ideas for new, lower cost health care ... affordable and efficient chronic disease management and preventive health ... is led by the von Liebig Entrepreneurism Center at ...
... health plans nationally may benefit consumers by lowering hospital ... are the most consolidated, according to a new RAND ... about 12 percent lower in the metropolitan areas ... view that when health plans become bigger they can ...
... usually reserved for designing buildings, bridges and aircraft has ... cancer patients. In a study published today, ... , researchers used computer-aided design (CAD) to create an ... as a visual aid to surgeons in tissue reconstruction ...
... ROCHESTER, Minn. -- A study by Mayo Clinic physician and ... Sandhya Pruthi, M.D. , and colleagues found that flaxseed ... among breast cancer patients and postmenopausal women. The study is ... Menopause . The randomized, placebo-controlled study followed ...
Cached Medicine News:Health News:HJF names 2011-12 fellowship award winners 2Health News:Macy Foundation report calls for sweeping graduate medical education reforms 2Health News:Macy Foundation report calls for sweeping graduate medical education reforms 3Health News:Macy Foundation report calls for sweeping graduate medical education reforms 4Health News:Accessible and affordable care at heart of health-care technology grants 2Health News:Accessible and affordable care at heart of health-care technology grants 3Health News:Accessible and affordable care at heart of health-care technology grants 4Health News:Accessible and affordable care at heart of health-care technology grants 5Health News:Accessible and affordable care at heart of health-care technology grants 6Health News:Accessible and affordable care at heart of health-care technology grants 7Health News:Consolidation of health plans may help lower hospital costs, study finds 2Health News:Computer-aided design used for breast tissue reconstruction 2Health News:Flaxseed no help for hot flashes during breast cancer or menopause, study finds 2
... immunosorbent assay method for the semi-quantitative determination ... human serum. The results of the anti-Gliadin ... aid in the diagnosis of diseases associated ... Coeliac Disease. Levels of these autoantibodies are ...
... a high throughput primary or backup ... offers performance and reliability equal to ... instruments. The advanced technology of the ... strips delivers reproducible and accurate results, ...
... assay was originally developed for the World ... ovarian function. It has been widely used ... of natural family planning methods. Urine samples ... concentration measured by EIA (enzyme labelled immunoassay ...
... 10-8700 ACTIVE® Estrone Enzyme Immunosorbent Assay ... quantitative measurement of Estrone in serum. ... of enzyme immunoassay where there is ... an enzyme-labeled antigen for a fixed ...
Medicine Products: